IL-17A in the treatment of nail psoriasis

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

BACKGROUND: Psoriasis is an inflammatory skin disease that significantly worsens the quality of the patients’ life. With vulgar psoriasis, the most common form of the disease, nail damage is observed in more than 50% of cases.

AIMS: To evaluate the efficacy and tolerability of secukinumab in the treatment of nail psoriasis (psoriatic onychodystrophy) in real clinical practice.

MATERIALS AND METHODS: The study was carried out on the basis of the Clinic for Skin and Venereal Diseases. V.A. Rakhmanov Sechenov University. The participants were 12 patients diagnosed with psoriasis, aged 29 to 60 years. All patients were diagnosed with a severe degree, 2 (16.7%) patients ― psoriatic erythroderma, 10 (83.3%) ― psoriasis vulgaris, all studied patients had nail plate lesions. All patients were treated with a genetically engineered biological drug ― an IL-17A inhibitor secukinumab (Cosentix), 300 mg subcutaneously once a week (5 injections), followed by a maintenance dose of 300 mg once a month. The course of therapy was 20 weeks (9 injections). Assessment of the severity of nail psoriasis and the effectiveness of therapy was carried out using indices: NAPSI (index of the degree of damage to the nail plates), DLQI (dermatological index of quality of life), which were studied in dynamics before treatment and after 20 weeks of treatment.

RESULTS: The NAPSI index was 25.3±3.4 points before treatment, and at week 20 it decreased to 2.2±0.7 points. These results demonstrate a regression of clinical manifestations by more than 80% from the initial state of the nails. When assessing the dermatological index of quality of life (DLQI), it was found that in the study group of patients before the start of treatment, it was 27.4±2.1 points, which reflected a strong negative effect of psoriasis on the quality of life of patients. After treatment, this indicator was 3.1±0.5 points among all patients. No patient experienced any side effects from the therapy.

CONCLUSIONS: Secukinumab is a highly effective and safe drug for the treatment of nail psoriasis in patients with vulgar psoriasis and psoriatic erythroderma and contributes to improve the quality of the patients’ life.

About the authors

Olga Yu. Olisova

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: olisovaolga@mail.ru
ORCID iD: 0000-0003-2482-1754
SPIN-code: 2500-7989

MD, Dr. Sci. (Med.), Professor

Russian Federation, Moscow

Victoria O. Nikuradze

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Author for correspondence.
Email: victorianikuradze@gmail.com
ORCID iD: 0000-0002-4674-8327

Graduate Student

Russian Federation, 8, Trubetskaya st., Moscow, 119991

Maria A. Koroleva

Central Clinical Hospital of the Management Affair of President Russian Federation

Email: victorianikuradze@gmail.com
ORCID iD: 0000-0002-7635-6260
Russian Federation, Moscow

References

  1. Jiaravuthisan MM, Sasseville D, Vender RB, et al. Psoriasis of the nail: anatomy, pathology, clinical presentation, and a review of the literature on therapy. J Am Acad Dermatol. 2007;57(1):1–27. doi: 10.1016/j.jaad.2005.07.073
  2. Klaassen KM, van de Kerkhof PC, Pasch MC. Nail psoriasis: a questionnaire-based survey. Br J Dermatol. 2013;169(2):314–319. doi: 10.1111/bjd.12354
  3. Williamson L, Dalbeth N, Dockerty JL, et al. Extended report: nail disease in psoriatic arthritis —clinically important, potentially treatable and often overlooked. Rheumatology (Oxford). 2004;43(6):790–794. doi: 10.1093/rheumatology/keh198
  4. Salomon J, Szepietowski JC, Proniewicz A. Psoriatic nails: a prospective clinical study. J Cutan Med Surg. 2003;7(4):317–321. doi: 10.1007/s10227-002-0143-0
  5. Maejima H, Taniguchi T, Watarai A, Katsuoka K. Evaluation of nail disease in psoriatic arthritis by using a modified nail psoriasis severity score index. Int J Dermatol. 2010;49(8):901–906. doi: 10.1111/j.1365-4632.2009.04452.x
  6. Langenbruch A, Radtke MA, Krensel M, et al. Nail involvement as a predictor of concomitant psoriatic arthritis in patients with psoriasis. Br J Dermatol. 2014;171(5):1123–1128. doi: 10.1111/bjd.13272
  7. Suskova VS, Pinson IYa, Olisova OY. Immunopathological mechanisms of psoriasis. Clinical Dermatology and Venereology. 2006;4(1):68–70. (In Russ).
  8. Dawber R. Fingernail growth in normal and psoriatic subjects. Br J Dermatol. 1970;82(5):454–457. doi: 10.1111/j.1365-2133.1970.tb02205.x
  9. Heydendael VM, de Borgie CA, Spuls PI, et al. The burden of psoriasis is not determined by disease severity only. J Investig Dermatol Symp Proc. 2004;9(2):131–135. doi: 10.1111/j.1087-0024.2004.09115.x
  10. Fortune DG, Main CJ, O’Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical vari-ables and psoriasis-specific stress. Br J Dermatol. 1997;137(5):755–760.
  11. Rapp SR, Feldman SR, Exum ML, et al. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41(3 Pt 1):401–407. doi: 10.1016/s0190-9622(99)70112-x
  12. Krueger G, Koo J, Lebwohl M, et al. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol. 2001;137(3):280–284.
  13. Touw CR, Hakkaart-Van Roijen L, Verboom P, et al. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol. 2001;144(5):967–969 doi: 10.1046/j.1365-2133.2001.04183.x
  14. Yaemsiri S, Hou N, Slining MM, He K. Grow thrate of human fingernails and toenails in healthy American young adults. J Eur Acad Dermatol Venereol. 2010;24(4):420–423. doi: 10.1111/j.1468-3083.2009.03426.x
  15. Pasch MC. Nail psoriasis: a review of treatment options. Drugs. 2016;76(6):675–705. doi: 10.1007/s40265-016-0564-5
  16. Luger TA, Barker J, Lambert J, et al. Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis. J Eur Acad Dermatol Venereol. 2009;23(8):896–904. doi: 10.1111/j.1468-3083.2009.03211.x
  17. De Vries AC, Bogaards NA, Hooft L, et al. Interventions for nail psoriasis. Cochrane Database Syst Rev. 2013;1:CD007633. doi: 10.1002/14651858.CD007633.pub2
  18. Klaassen KM, van de Kerkhof PC, Bastiaens MT, et al. Scoring nail psoriasis. J Am Acad Dermatol. 2014;70(6):1061–1066. doi: 10.1016/j.jaad.2014.02.010
  19. Singh K, Argáez C. Cyclosporine for moderate to severe plaque psoriasis in adults: a review of clinical effectiveness and safety. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018.
  20. Olisova OYu, Teplyuk NP, Pinegin VB. Modern methodes of psoriasis treatment. Russian Journal of Medicine. 2015;(9):483–486. (In Russ).
  21. Langley RG, Saurat JH, Reich K. Recommendations for the treatment of nail psoriasis in patients with moderate to severe psoriasis: a dermatology expert group consensus. J Eur Acad Dermatol Venereol. 2012;26(3):373–381. doi: 10.1111/j.1468-3083.2011.04349.x

Supplementary files

Supplementary Files
Action
1. JATS XML
Download
2. Fig. 1. Patient A., nail psoriasis: а ― before treatment; б ― after 12 weeks of treatment (7 injections).

Download (130KB)
Indexing metadata
3. Fig. 2. Patient B., nail psoriasis: а ― before treatment; б ― after 20 weeks of treatment (9 injections).

Download (298KB)
Indexing metadata
4. Fig. 3. Patient V., psoriasis of the nails of the feet: а ― before treatment; б ― after 20 weeks of treatment (9 injections).

Download (234KB)
Indexing metadata

Copyright (c) 2021 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies